Table 3 Studies of molecular targeted therapies in ACC, MEC and ADC of salivary glands

Guigay et al ⁴⁹

Imatinib 400 mg twice daily

17

2

-

-

-

-

Slevin et al ⁵⁰

Imatinib 800 mg daily for 2 months, if stable disease: P 80 mg/m² every 3w + Imatinib 400 mg daily

18

0

-

-

-

-

Ochel et al ⁵¹

Imatinib 400 mg daily

4

0

-

-

-

-

Lin et al ⁵²

Imatinib 400 mg twice daily

5

0

-

-

-

-

Hotte et al ⁵³

Imatinib 40 mg twice daily

16

0

-

-

-

-

Pfeffer et al ⁵⁴

Imatinib 400 mg daily, with possible escalation to 800 mg

10

0

-

-

-

-

Alcedo et al ⁵⁵

Imatinib 400-600 mg daily

2

2

-

-

-

-

Faivre et al ⁵⁶

Imatinib 800 mg daily

8

0

-

-

-

-

Glisson et al ⁵⁸

Gefitinib 250 mg daily

19

0

2

0

3

0

Agulnik et al ⁵⁹

Lapatinib 1500 mg daily

19

0

2

0

7

0

Locati et al ⁶⁰

Cetuximab 400 mg/m² loading dose, then 250 mg/m² weekly.

23

0

2

0

1

0

Haddad et al ⁷⁷

Trastuzumab: 4 mg/kg loading dose, then 2 mg/kg weekly.

2

0

3

1

7

0

Argiris et al ⁸³

Bortezomib 1.3 mg/m² days 1,4,8,11 every 3 weeks. At progression: doxorubicin 20 mg/m² days 1,8.

25

0

-

-

-

-